Takeda Pharmaceutical stock declines to 4,926 yen on June 5 following disclosure of legal provision and earnings report revision.

On June 5, Takeda disclosed an additional provision for legal proceedings and a revision to the fiscal year ended March 31, 2026 earnings report (IFRS, consolidated). The stock fell from 5,118 yen on May 29 to 4,926 yen on June 5, with trading volume surging 103% on May 29.

On June 3, the stock reached a year-to-date low of 4,710 yen before recovering on June 5 with a gain of 1.57%, creating conditions for wider price swings in subsequent sessions.

A major U.S. securities firm raised its target price to 6,300 yen on June 3 and maintained a bullish rating. Separately, MSMUFG raised its target price on June 4 and signaled new drug catalysts accelerating in the July–September period. Analyst consensus for the fiscal year ending March 27 (fiscal 2027) operating profit rose 3.5% on June 3.